Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drug dosing showdown: can fewer injections still control wet AMD?

NCT ID NCT04679935

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two different dosing schedules of brolucizumab (Beovu) in 52 people with wet age-related macular degeneration (AMD) who had not responded well to previous treatment. Participants received the drug as an eye injection either on a fixed schedule or with adjustments based on their eye health. The goal was to see which schedule better maintained vision and controlled the disease over 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
brolucizumab (Beovu), an anti-VEGF drug given as an eye injection
What this could lead to
If successful, this could help doctors choose a better dosing schedule for brolucizumab to control wet AMD with fewer injections.
What could go wrong
This is a small, completed Phase 4 study with only 52 participants, so results may not apply to all patients. The drug can cause eye inflammation or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration choroidal neovascularization eye disorder Geographic Atrophy macular degeneration retinal degeneration retinal disorder vision disorder wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

  • Novartis Investigative Site

    Regensburg, Bavaria, 93053, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60549, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Bonn, 53105, Germany

  • Novartis Investigative Site

    Düsseldorf, 40225, Germany

  • Novartis Investigative Site

    Göttingen, 37075, Germany

  • Novartis Investigative Site

    Hanover, 30625, Germany

  • Novartis Investigative Site

    Homburg, 66421, Germany

  • Novartis Investigative Site

    Leipzig, 04103, Germany

  • Novartis Investigative Site

    Lübeck, 23538, Germany

  • Novartis Investigative Site

    Magdeburg, 39120, Germany

  • Novartis Investigative Site

    Mainz, 55131, Germany

  • Novartis Investigative Site

    Marburg, 35039, Germany

  • Novartis Investigative Site

    Münster, 48149, Germany

  • Novartis Investigative Site

    Neubrandenburg, 17036, Germany

  • Novartis Investigative Site

    Ulm, 89075, Germany

  • Novartis Investigative Site

    Lausanne, CHE, 1000, Switzerland

  • Novartis Investigative Site

    Bern, 3007, Switzerland

  • Novartis Investigative Site

    Zurich, 8063, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.